BiotechTube
Phoenestra

Phoenestra

Vienna, Austria
phoenestra.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Phoenestra is a Vienna-based biotech advancing a pipeline of stem cell-derived extracellular vesicle (EV) therapeutics through its GMP-aligned EVscale™ manufacturing platform. The company's lead program is in pre-clinical development for diabetic wound treatment, with other undisclosed regenerative medicine indications under investigation. Operating as a private entity, Phoenestra combines therapeutic development with R&D and upcoming GMP services, positioning itself at the intersection of advanced bioprocessing and regenerative medicine.

OncologyImmunologyRegenerative Medicine

Technology Platform

EVscale™ - A GMP-aligned, scalable manufacturing platform for producing extracellular vesicles (EVs/exosomes) from mesenchymal stem cells (MSCs) and induced pluripotent stem cells (iPSCs). It features bioreactor-based cell expansion, a patented continuous perfusion harvest, and gentle purification to preserve biological activity.

Opportunities

The large and growing unmet need in diabetic wound care represents a multi-billion dollar market opportunity for a safe, effective, and scalable biologic therapy.
The company's hybrid model of therapeutic development paired with CRO-like services provides an early revenue stream and validates its platform with external clients.

Risk Factors

The regulatory pathway for EV-based therapeutics is still evolving, creating uncertainty.
As a pre-clinical company, it faces significant technical risk that its products may not demonstrate efficacy or safety in human trials.
Competition in the EV space is intensifying rapidly.

Competitive Landscape

Phoenestra operates in the competitive and fast-evolving field of extracellular vesicle therapeutics, competing with both dedicated EV biotechs (e.g., Codiak BioSciences, Evox Therapeutics) and large pharma exploring the modality. Its key differentiator is its integrated, GMP-ready manufacturing platform (EVscale™) focused on scalability and reproducibility from the outset.

More companies in Cell & Gene Therapy →More companies in Austria →